March Roundup: That’s a Wrap for a Busy Q1
It’s been a busy year so far. And we’re only at the start of April! Find out what we’ve been up to in this blog.
Capture Exhilarating High-Throughput Capabilities
While you may not find yourself Kitesurfing in Barbados, intuitive cell line selection unleashing powerful high throughput capabilities promises to be exhilarating.
How Clean is Your Kitchen? Using Analogies to Explain the Value of Digital Solutions
For those of us who develop software that supports the biopharmaceutical/life science industry, the challenges and opportunities in digital transformation are painfully obvious and it can be easy to forget that not everyone sees it that way. Let’s try another way…
Unlocking the Power of Advanced Analytics in Life Sciences
While 2021 was another challenging year in many respects, the life science industry still managed some notable achievements.
A More Sustainable Future for Pharma is Possible
The global community await to hear what the accelerated response to climate change will be from the COP26 Summit starting on Sunday in Glasgow. Here at IDBS we know that identification of true reductions in environmental impact through process modelling and Life Cycle Assessment can only be made with access to quality data. Find out more in our blog.
On the Road to BioPharma 4.0
There was a flurry of activity on social media in June when John Erickson et al. published in Biotechnology and Bioengineering on end-to-end collaboration to transform development and manufacturing of biopharmaceuticals.
Beating the Capacity Crunch: Rethinking the Biopharma Supply Chain to Avoid Shortages
One of the lasting legacies of the COVID-19 pandemic is heightened awareness of manufacturing challenges and supply chain vulnerabilities in the biopharma industry and the impact this can have on public health. Issues have occurred at every stage of the supply chain, from the availability of raw materials to quality concerns with active pharmaceutical ingredients (APIs), and finished dosage forms and restrictive cold chain requirements.
Adapting to the Challenge COVID-19 Presents to Create a New Biopharma Normal
In a recent Forbes article, Danaher’s Chief Science officer, Jose-Carlos Gutierrez-Ramos, described the impact of the COVID-19 pandemic as follows:“I believe the biopharma business model has fundamentally changed.
Drug Safety and the Public Consciousness
The public consciousness has been flooded with awareness of the previously niche concerns of quality control in drug manufacturing.
Biologics are Changing Our World. How Can We Speed Up Their Development?
The global pandemic is shining a spotlight on the power of biologics, both vaccines and antibody therapeutics, to prevent serious infections and treat disease.
